Table: q1_q4_2020_prescription_drugs_intro_to_market , manufacturer_name like Z*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name ndc_number drug_product_description date_introduced_to_market wac_at_introduction marketing_pricing_plan_description marketing_pricing_plan_non_public_indicator estimated_number_of_patients breakthrough_therapy_indicator priority_review_indicator acquisition_date acquisition_price acquisition_price_non_public_indicator acquisition_price_comment general_comments supporting_documents
Zydus Pharmaceuticals (USA) Inc. 70710151709 Fondaparinux Inj 10mg/0.8ml (2x0.8ml) 2020-01-13 950.6000 None 1 None None None None None None None Please note that the WAC represented is WAC for a 30 day course of treatment based on Zydus dosing assumption. Zydus dosing assumption is 10mg per day for 9 days. This is an AP rated generic product. Zydus is not the ANDA holder for this product but is the sales and marketing partner. Acquisition date and price are not applicable as the drug was not acquired. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710151406 Fondaparinux Inj 2.5mg/0.5ml (10x0.5ml) 2020-01-13 705.0000 None 1 None None None None None None None Please note that the WAC represented is WAC for a 30 day course of treatment based on Zydus dosing assumption. Zydus dosing assumption is 2.5mg per day for 32 days. This is an AP rated generic product. Zydus is not the ANDA holder for this product but is the sales and marketing partner. Acquisition date and price are not applicable as the drug was not acquired. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710151409 Fondaparinux Inj 2.5mg/0.5ml (2x0.5ml) 2020-01-13 1211.7000 None 1 None None None None None None None Please note that the WAC represented is WAC for a 30 day course of treatment based on Zydus dosing assumption. Zydus dosing assumption is 2.5mg per day for 32 days. This is an AP rated generic product. Zydus is not the ANDA holder for this product but is the sales and marketing partner. Acquisition date and price are not applicable as the drug was not acquired. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710151509 Fondaparinux Inj 5mg/0.4ml (2x0.4ml) 2020-01-13 950.6000 None 1 None None None None None None None Please note that the WAC represented is WAC for a 30 day course of treatment based on Zydus dosing assumption. Zydus dosing assumption is 5mg per day for 9 days. This is an AP rated generic product. Zydus is not the ANDA holder for this product but is the sales and marketing partner. Acquisition date and price are not applicable as the drug was not acquired. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710151609 Fondaparinux Inj 7.5mg/0.6ml (2x0.6ml) 2020-01-13 950.6000 None 1 None None None None None None None Please note that the WAC represented is WAC for a 30 day course of treatment based on Zydus dosing assumption. Zydus dosing assumption is 7.5mg per day for 9 days. This is an AP rated generic product. Zydus is not the ANDA holder for this product but is the sales and marketing partner. Acquisition date and price are not applicable as the drug was not acquired. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710113301 Chlorpromazine HCl 200mg Tab 2020-02-11 989.3500 None 1 None None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710153001 Doxorubicin Hydrochloride 20mg/10mL Liposomal Injection 2020-09-29 969.0000 None 1 None None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally, nor do we have access to any information which would indicate the number of patients in the United States with the condition(s) for which our products may be prescribed. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None
Zydus Pharmaceuticals (USA) Inc. 70710153101 Doxorubicin Hydrochloride 50mg/25mL Liposomal Injection 2020-09-29 2422.5500 None 1 None None None None None None None This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures/sells generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We determine manufacturing volumes based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. None